Projects Commercialization
1. Multimedia Projects
Israel as a young and culturally diversified has its unique TV’s watching rates and considers as one of the highest consumptive nations of cable and satellite transmissions.
Penetration rates to the Israeli markets are extremely high, but there is no doubt that focusing on the right characteristics of each sector is a mission that must be tackled in order to maximize profits and to gain a larger share in the markets.
The Arab sector in Israel is a minority but during recent years it has managed to become one of the most influential and larger minority’s sectors in Israel but with no appropriate focusing on its needs.
The Arab sector is in a split between its stance towards the place it lives in and by the fact that they are part of the Arab Nation with different cultural characteristics which make them limiting social differences in villages and neighborhoods, hence separating them from the main stream.
There is no doubt that the world is moving towards more egalitarian societies where depriving of others will no longer be a part of the western world. Technological progress has a major part in these trends and it is a matter of time till cultural characteristics pertaining to diversified sectors will be diminished.
The above mentioned concepts lead to a claiming that by gathering a greater share using contemporary differences, will allow sophisticated corporations to gain larger share of the media markets. This is a game that most of the multimedia corporations are aware to, thus striving to increase their share by targeting sectors.
Neton Enterprises has decided to handle these challenges and to gather all of its Arab Media clients, by using their cultural differences as a business leverage and to penetrate to the multi media markets.
Business differences which are pertained to cultural differences can be divided into 3 major parts:
- Different cultural flavour regarding sorts of programs that are preferred by minorities
- Receivable's monies collection technique
- Crowded neighborhoods and inclosing features that makes it difficult to communicate with populations that are quite suspicious when dealing with long range official matters such as multimedia subscriptions. It is easier to sell using local salespeople than using foreigners.
For this reasons we have signed on agreements with local technicians that are part of the media industry especially satellite’s assembling and other related equipment for organizing them in one big corporation that markets its media content to unique niches which are not a part of the main stream.
The same relates to other immigrants that are part of every society in the western world that wish to have better lives for themselves and for their off springs, till more cultural equality is prevailed and issued by the mutual authorities of all citizens.
2. Political Social Networking
To review what people from different regions, religions and cultures think consumes time and it is quite hard to follow. These activities of political blogs affect public’s perceptions and views, but do not have steady and reliable podiums in which their views are categorized and sorted, thus tracing and analyzing what people think or do or affecting others regarding social and political issues, still makes contradictions and disputes.
Face-Book evolved by gathering of people around the globe by developing social networking. These networks allow people to mingling, sharing views and discussing fun and business matters for publishing their concepts and views along with abundant goods and services that have to be concisely pointed, lest it won’t reach to public’s awareness and consciousness.
Linked-In, as a professional network, focuses on professional issues thus bypasses all kinds of social networking for fun or pleasure. Fllowing that, Linked-In aims to developing of business relations between entities and professionals.
When people, young or old, women or men, wish to express their feeling and views, they must look for specific blogs discussing subjects that dissipate after a while because of feeble means to following them.
Neton Enterprises decided to establish the world's parliament, the same as Face Book and linked-In did for general and professional purposes in respective and as an alter conceptual place where people with political and social ambitions can steer worlds and local moves.
The aforesaid networking will entitle each parliament member (also contenders) the ability to promote themselves to new positions under elections that are performed by the website's parliament bureau that directs and manages data flows of each region.
This can be one of the world’s important resources for public and political views that are part of the world’s mutual interests and also the most reliable source of analyzing social and political trends.
For establishing it, Neton has signed agreements with subcontractors to programming and designing of the world's parliament website and also located regional franchisees to administrate data, monitoring messages and also promote it to official institutions by analyzing social trends that are part of contemporary political events as we can see in many Arab and totalitarians states.
We believe that it may instigate exchanging of views thus letting politicians sense what their electorates wish for and how to handle them in more efficient and constructive ways.
We also allow our subscribers(parliament members) to be recognized by disseminating social views that are structured and monitored for other contenders to vote for.
Development and promoting of such international website is a complicated technological matter that needs the best specialists to plan, program and design. We have begun issuing our initial moves including patent’s registrations in some western nations and also expanding it to other countries as well.
3. Diabetes
Type 2 diabetics (T2D) is a major burden worldwide due to its high and increasing prevalence, the severity and high socioeconomic cost of its complications for which effectiveness of current therapies is less than 50%. For these reasons, diabetes is striving for innovative therapeutic products from the pharmaceutical or nutraceutical industries. The discussed invention is highly innovative for targeting T2D. However, challenges pertain to technical issues in highly regulated pharmaceutical and clinical sectors including numerous barriers to marketing it as innovative cure, will be tackled.
To do more with less, companies must collaborate with each other coordinating essential strategies of productivity, efficiency and elimination of waste especially for R&D of new therapeutic entities. Many of the novel drugs in T2D are developed by conglomerates of pharmaceutical firms that usually remain competitors in other areas. These associations are beneficial for market penetration and retention as well as for optimization of financial resources through the development phases of any pharmaceutical products. The necessity for collaboration is even more vital for the biotechnology sector including the nutraceutical sector that is composed of relatively small size companies and with limited resources.
These considerations are the cause for the creation of a Consortium composed of several entities. An Israeli IP firm, Canadian firms in Montreal that conducts high level science & clinical research programs aimed at delivering of personalized medicine with particular emphasis of T2D, manufacturers based in Canada specializing in botanical-pharmaceutical arena that uses novel therapeutic techniques
4. Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a common and chronic debilitating disease causing swollen and deformed joints, inflicting severe pain, leading to loss of productivity and other functional disabilities. Treating RA is a costly, long-term proposition, requiring ongoing therapies, caregivers, and more.
An estimated 40 million Americans suffer from rheumatic conditions, which are projected to reach 59 million by 2020. Rheumatoid arthritis represents 10% of this figure. Treatment and management of rheumatoid arthritis is estimated at $20 billion per year in the United States.
Currently, there is no cure for RA. Traditional treatment is primarily directed at relieving pain, reducing inflammation, and preventing joint deformity. Available drugs and treatments (such as radiotherapy), and newer biological drugs (such as anti-TNF drugs), are non-specific and often have side effects.
The IP firm is developing a humanized monoclonal antibody that selectively targets the pathological cells involved in the inflammatory process.
The antibody recognizes a specific protein expressed on the surface of pathological inflammatory cells, which destroy the bone and the cartilage of the RA patient.This protein is not expressed on normal cells. Interaction of anti- with the inflammatory cells kills these cells by a mechanism called apoptosis. Injection of antibodies into mice with collagen-induced arthritis (analogous to human rheumatoid arthritis) at the onset of disease markedly reduces the pathological activity. The humanized version of protein has been already produced by The IP firm. This achievement represents the first therapy specifically aimed at rheumatoid arthritis.
The IP firm RA has produced a monoclonal antibody protein which the company will license the monoclonal antibody to a large pharmaceutical company for further development and clinical trials. The IP firm expects sales to begin in 2018.
The same relates to other immigrants that are part of every society in the western world that wish to have better lives for themselves and for their off springs, till more cultural equality is prevailed and issued by the mutual authorities of all citizens.
2. Political Social Networking
To review what people from different regions, religions and cultures think consumes time and it is quite hard to follow. These activities of political blogs affect public’s perceptions and views, but do not have steady and reliable podiums in which their views are categorized and sorted, thus tracing and analyzing what people think or do or affecting others regarding social and political issues, still makes contradictions and disputes.
Face-Book evolved by gathering of people around the globe by developing social networking. These networks allow people to mingling, sharing views and discussing fun and business matters for publishing their concepts and views along with abundant goods and services that have to be concisely pointed, lest it won’t reach to public’s awareness and consciousness.
Linked-In, as a professional network, focuses on professional issues thus bypasses all kinds of social networking for fun or pleasure. Fllowing that, Linked-In aims to developing of business relations between entities and professionals.
When people, young or old, women or men, wish to express their feeling and views, they must look for specific blogs discussing subjects that dissipate after a while because of feeble means to following them.
Neton Enterprises decided to establish the world's parliament, the same as Face Book and linked-In did for general and professional purposes in respective and as an alter conceptual place where people with political and social ambitions can steer worlds and local moves.
The aforesaid networking will entitle each parliament member (also contenders) the ability to promote themselves to new positions under elections that are performed by the website's parliament bureau that directs and manages data flows of each region.
This can be one of the world’s important resources for public and political views that are part of the world’s mutual interests and also the most reliable source of analyzing social and political trends.
For establishing it, Neton has signed agreements with subcontractors to programming and designing of the world's parliament website and also located regional franchisees to administrate data, monitoring messages and also promote it to official institutions by analyzing social trends that are part of contemporary political events as we can see in many Arab and totalitarians states.
We believe that it may instigate exchanging of views thus letting politicians sense what their electorates wish for and how to handle them in more efficient and constructive ways.
We also allow our subscribers(parliament members) to be recognized by disseminating social views that are structured and monitored for other contenders to vote for.
Development and promoting of such international website is a complicated technological matter that needs the best specialists to plan, program and design. We have begun issuing our initial moves including patent’s registrations in some western nations and also expanding it to other countries as well.
3. Diabetes
Type 2 diabetics (T2D) is a major burden worldwide due to its high and increasing prevalence, the severity and high socioeconomic cost of its complications for which effectiveness of current therapies is less than 50%. For these reasons, diabetes is striving for innovative therapeutic products from the pharmaceutical or nutraceutical industries. The discussed invention is highly innovative for targeting T2D. However, challenges pertain to technical issues in highly regulated pharmaceutical and clinical sectors including numerous barriers to marketing it as innovative cure, will be tackled.
To do more with less, companies must collaborate with each other coordinating essential strategies of productivity, efficiency and elimination of waste especially for R&D of new therapeutic entities. Many of the novel drugs in T2D are developed by conglomerates of pharmaceutical firms that usually remain competitors in other areas. These associations are beneficial for market penetration and retention as well as for optimization of financial resources through the development phases of any pharmaceutical products. The necessity for collaboration is even more vital for the biotechnology sector including the nutraceutical sector that is composed of relatively small size companies and with limited resources.
These considerations are the cause for the creation of a Consortium composed of several entities. An Israeli IP firm, Canadian firms in Montreal that conducts high level science & clinical research programs aimed at delivering of personalized medicine with particular emphasis of T2D, manufacturers based in Canada specializing in botanical-pharmaceutical arena that uses novel therapeutic techniques
4. Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a common and chronic debilitating disease causing swollen and deformed joints, inflicting severe pain, leading to loss of productivity and other functional disabilities. Treating RA is a costly, long-term proposition, requiring ongoing therapies, caregivers, and more.
An estimated 40 million Americans suffer from rheumatic conditions, which are projected to reach 59 million by 2020. Rheumatoid arthritis represents 10% of this figure. Treatment and management of rheumatoid arthritis is estimated at $20 billion per year in the United States.
Currently, there is no cure for RA. Traditional treatment is primarily directed at relieving pain, reducing inflammation, and preventing joint deformity. Available drugs and treatments (such as radiotherapy), and newer biological drugs (such as anti-TNF drugs), are non-specific and often have side effects.
The IP firm is developing a humanized monoclonal antibody that selectively targets the pathological cells involved in the inflammatory process.
The antibody recognizes a specific protein expressed on the surface of pathological inflammatory cells, which destroy the bone and the cartilage of the RA patient.This protein is not expressed on normal cells. Interaction of anti- with the inflammatory cells kills these cells by a mechanism called apoptosis. Injection of antibodies into mice with collagen-induced arthritis (analogous to human rheumatoid arthritis) at the onset of disease markedly reduces the pathological activity. The humanized version of protein has been already produced by The IP firm. This achievement represents the first therapy specifically aimed at rheumatoid arthritis.
The IP firm RA has produced a monoclonal antibody protein which the company will license the monoclonal antibody to a large pharmaceutical company for further development and clinical trials. The IP firm expects sales to begin in 2018.
Net-On ltd.
